The CSL share price return tripled the ASX 200 in November

November saw a very healthy return for CSL shares.

| More on:
A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price had a very impressive month in November 2023, rising by around 13%. That was a much stronger return than the S&P/ASX 200 Index (ASX: XJO) which rose by 4.5%.

As we can see on the chart above, the CSL share price has bounced from its 2023 low, but it's still over 15% lower than its 2023 high.

What happened in November?

It was a slow news month for the company last month, it didn't announce anything noteworthy at all.

However, in the middle of October, it did release a 'capital markets day' presentation that did include a number of positives – it's up more than 9% since then.

CSL pointed out it's the global number one in plasma protein therapies (a $38 billion industry), it's the global number two in flu vaccines (a $7 billion industry) and it's the global number one in iron deficiency (a $5 billion industry).

The ASX healthcare share said it's positioned for annual double-digit earnings growth because it operates in high-growth markets where it has durable products driven by "continued innovation and embedded know-how".

It also pointed to "yield enhancement" across plasma and manufacturing platforms and it's investing in immunoglobulin and cell capacity.

In terms of research and development, it's investing for growth, with near-to-mid-term launches and there are "longer-term opportunities across platforms and therapeutic areas."

CSL also revealed that it's looking to use generative AI to potentially do a number of things including accelerate the time to trial, improve 'pharmacovigilance' reporting, improve the patient experience, improve tenders, optimise inventory management, improve the donor experience and improve "enterprise search".

CSL shares viewed as a cheaper opportunity

During the month of November, we saw a few different experts call CSL shares a buy, including brokers. As reported by my colleague James Mickleboro, Goldman Sachs is expecting CSL to achieve higher profit margins and this could deliver stronger shareholder returns.

But, with the CSL share price now higher than a few weeks ago, the forward price/earnings (P/E) ratio is now not as cheap as it was. According to the projection on Commsec, the CSL share price is now valued at 28 times FY24's estimated earnings.

Should you invest $1,000 in CSL right now?

Before you buy CSL shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and CSL wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Goldman Sachs Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Healthcare Shares

Guess which ASX 200 stock is jumping 16% on big news

Let's find out what news is getting investors excited this afternoon.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Healthcare Shares

Why is this ASX 300 stock crashing 18% today?

Investors are rushing to the exits. But why? Let's look into things.

Read more »

Health professional working on his laptop.
Healthcare Shares

Are CSL shares at risk from the Trump tariffs?

How exposed are CSL shares to potential Trump medicinal tariffs?

Read more »

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

What did CSL have to say at Macquarie's 2025 conference?

Does this business have a healthy growth outlook?

Read more »

smiling health care workers in a medical setting
Healthcare Shares

Sonic Healthcare shares are down more than 40% since 2021. Will its AI initiative be the catalyst for a turnaround?

Could AI spark a recovery for this ASX healthcare stock?

Read more »